DS Healthcare Group Appoints Dr. Brijeshkumar Patel, PhD as Head of R&D to
Advance the Science Behind the Company's Industry Leading Personal Care
R&D efforts focused on development of topical drug delivery systems for
hair-care and skin-care applications
Pompano Beach, Fla., May 21, 2014 (GLOBE NEWSWIRE) -- DS Healthcare Group,
Inc.(NASDAQ: DSKX), a leading developer of personal care products and
specialty pharmaceuticals, today announced it has appointed Dr. Brijeshkumar
Patel, PhD to the newly created position of Director of Research and
Development. In this role Dr. Patel will focus on the development of
transdermal drug delivery systems for the Company's hair-care products, as
well as restructuring existing and new molecules for increased absorption and
effectiveness. He will work alongside a team of chemists both within DS
Healthcare and with the Company's external consultants to develop skin-care
applications. In addition to maintaining the highest quality controls for the
Company's over-the-counter formulations, Dr. Patel will also collaborate with
Aptiv Solutions, DS Healthcare's clinical research organization (CRO) on the
Company's prescription-grade hair formulation currently under development.
"We are executing on the pursuit of science that enhances hair regrowth and
youthful skin. Dr. Patel joins us as Director of R&D to lead our clinical
development efforts for both our prescription hair loss development program
and our portfolio of over-the-counter hair care and skin care products,"
stated DS Healthcare President and CEO Daniel Khesin. "We've seen demand for
our over-the-counter products continue to grow based on the performance of our
proprietary, patent-pending formulations. With Dr. Patel on our team, we
believe we will be in a position to accelerate our innovation and clinical
programs with a goal towards expanding our intellectual property, product
portfolio and corresponding revenues."
Dr. Patel has over 7 years of research experience in developing novel drug
delivery systems for pulmonary, oral and topical delivery of small molecules
and peptide drugs. He brings to DS Healthcare specific expertise in designing
preclinical and clinical study protocols. He has authored 10 articles
published in peer-reviewed scientific publications and delivered over a dozen
poster and oral presentations at scientific conferences. Dr. Patel received
his Ph.D. in Pharmaceutical Sciences from the Graduate School of Biomedical
Sciences, Texas Tech University Health Sciences Center. He also earned his
M.S. in Pharmaceutical Sciences from the School of Pharmacy, Campbell
University, and his B.S. in Pharmaceutical Sciences from the Shri B M Shah
College of Pharmaceutical Education and Research, HNGU, India.
DS Healthcare Group recently announced its intention to file an
Investigational New Drug application with the U.S. Food and Drug
Administration for a topical hair loss treatment. If approved, it would be the
third FDA-approved treatment for hair loss and only the second topical
treatment. The Company has recently filed two patents for its prescription and
over-the-counter hair loss formulations.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development of biotechnology for topical
therapies. It markets through online and specialty retailers, distributors,
cosmetics wholesalers, and salons. Its research has led to a highly innovative
portfolio of personal care products and additional innovations in
pharmaceutical projects. For more information on DS Healthcare Group's
flagship brand, visit www.dslaboratories.com
Except for statements of historical fact, the matters discussed in this press
release are forward-looking and made pursuant to the Safe Harbor provisions of
the Private Securities Litigation Reform Act of 1995. "Forward-looking
statements" describe future expectations, plans, results, or strategies, and
are generally preceded by words such as "future," "plan" or "planned,"
"expects," or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many of which
are beyond the company's control that may cause actual results to differ
materially from stated expectations. These risk factors include, among others,
limited operating history, difficulty in developing and marketing products,
intense competition, and additional risks factors as discussed in reports
filed by the company with the Securities and Exchange Commission, which are
available at http://www.sec.gov.
CONTACT: Laurel Moody
DS Healthcare Group,Inc.
Press spacebar to pause and continue. Press esc to stop.